Benefit of Risk Score-Guided Prophylaxis in Pregnant Women at Risk of Thrombotic Events: A Controlled Before-and-After Implementation Study

Abstract Background Management of pregnant women at risk of venous thromboembolism (VTE) and placental vascular complications (PVCs) remains complex. Guidelines do not definitively specify optimal strategies. Objective Our objective was to evaluate the impact of employing risk score-driven prophylaxis strategies on VTE and PVC rates in at-risk pregnant women. Materials and Methods This study, conducted in 21 French maternity units, compared VTE and PVC rates before and after implementation of a risk scoring system to determine prophylactic strategies. Results A total of 2,085 pregnant women at risk of VTE or PVC were enrolled. Vascular events occurred in 190 (19.2%) patients before and 140 (13.0%) after implementation of risk score-driven prophylaxis (relative risk [RR] = 0.68 [0.55; 0.83]). The incidence of deep vein thrombosis during pregnancy was reduced (RR = 0.30 [0.14; 0.67]). PVC comprised mainly pre-eclampsia, occurring in 79 patients before and 42 patients after risk score implementation (RR = 0.52 [0.36; 0.75]). Post-partum haemorrhage occurred in 32 patients (3.2%) before and 48 patients (4.5%) after risk score implementation (RR = 1.38 [0.89; 2.13], p = 0.15). Conclusion Use of a simple risk scoring system, developed by experts in VTE and PVC research to guide prophylaxis, reduced the risk of thrombotic events during pregnancy without any significant increase in bleeding risk.

[1]  I. Greer,et al.  Thrombophilia and Pregnancy Complications , 2015, International journal of molecular sciences.

[2]  J. D. de Vries,et al.  ALIFE2 study: low-molecular-weight heparin for women with recurrent miscarriage and inherited thrombophilia - study protocol for a randomized controlled trial , 2015, Trials.

[3]  M. Areia,et al.  Low-molecular-weight heparin plus aspirin versus aspirin alone in pregnant women with hereditary thrombophilia to improve live birth rate: meta-analysis of randomized controlled trials , 2015, Archives of Gynecology and Obstetrics.

[4]  J. Kingdom,et al.  Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial , 2014, The Lancet.

[5]  M. Di Nisio,et al.  Aspirin and/or heparin for women with unexplained recurrent miscarriage with or without inherited thrombophilia. , 2014, The Cochrane database of systematic reviews.

[6]  J. Gris,et al.  Meta-analysis of low-molecular-weight heparin to prevent recurrent placenta-mediated pregnancy complications. , 2014, Blood.

[7]  D. Veenstra,et al.  VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.

[8]  A. James.  Practice bulletin no. 123: thromboembolism in pregnancy. , 2011, Obstetrics and gynecology.

[9]  J. Gris,et al.  Enoxaparin for the secondary prevention of placental vascular complications in women with abruptio placentae , 2010, Thrombosis and Haemostasis.

[10]  J. Gris,et al.  Use of the Delphi method to facilitate antithrombotics prescription during pregnancy. , 2010, Thrombosis research.

[11]  M. Berman,et al.  The Epidemiology of Postpartum Hemorrhage in a Large, Nationwide Sample of Deliveries , 2010, Anesthesia and analgesia.

[12]  B. Brenner,et al.  Assessment and management of high-risk pregnancies in women with thrombophilia. , 2009, Blood reviews.

[13]  C. Négrier,et al.  A risk score for the management of pregnant women with increased risk of venous thromboembolism: a multicentre prospective study , 2009, British journal of haematology.

[14]  P. Sandset,et al.  Ante‐ and postnatal risk factors of venous thrombosis: a hospital‐based case–control study , 2008, Journal of thrombosis and haemostasis : JTH.

[15]  J. Hirsh,et al.  Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). , 2008, Chest.

[16]  D. Neuberg,et al.  Timing of postpartum enoxaparin administration and severe postpartum hemorrhage , 2008, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[17]  S. Laporte,et al.  Feasibility of an easy-to-use risk score in the prevention of venous thromboembolism and placental vascular complications in pregnant women: a prospective cohort of 2736 women. , 2008, Thrombosis research.

[18]  C. Négrier,et al.  Feasibility of an easy-to-use risk score in the prevention of venous thromboembolism and placental vascular complications in pregnant women. A rebuttal. , 2008, Thrombosis research.

[19]  M. Spannagl,et al.  Risk stratification and heparin prophylaxis to prevent venous thromboembolism in pregnant women , 2007, Thrombosis and Haemostasis.

[20]  J. Zehnder,et al.  Antithrombotic therapy and pregnancy: consensus report and recommendations for prevention and treatment of venous thromboembolism and adverse pregnancy outcomes. , 2007, American journal of obstetrics and gynecology.

[21]  D. Benhamou,et al.  Venous thromboembolism prevention in surgery and obstetrics: clinical practice guidelines , 2006, European journal of anaesthesiology.

[22]  J. Gris,et al.  Low-molecular-weight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder. , 2004, Blood.

[23]  B. Dahlbäck,et al.  Individual risk assessment of thrombosis in pregnancy , 2002, Acta obstetricia et gynecologica Scandinavica.

[24]  P. Bernstein,et al.  Risk factor scoring for predicting venous thromboembolism in obstetric patients. , 2000, American journal of obstetrics and gynecology.